Efficacy and Safety of Bimekizumab in Psoriatic Arthritis with Skin and Nail Involvement

Overview

Bimekizumab demonstrated clinically meaningful and sustained improvements across multiple disease domains in psoriatic arthritis patients with significant plaque psoriasis and nail involvement over one year. The treatment was well tolerated with no new safety concerns identified.

Background

Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting joints, skin, and nails, with nail involvement linked to more severe disease and worse quality of life. Patients with concomitant plaque-type psoriasis and nail symptoms experience greater disease impact and psychological distress. Effective therapies should target all core disease domains to improve overall patient outcomes. Bimekizumab, an antibody inhibiting IL-17A and IL-17F, has shown efficacy in PsA and moderate-to-severe plaque psoriasis in prior phase 3 studies.

Data Highlights

Bimekizumab 160 mg administered subcutaneously every 4 weeks was evaluated in biologic-naïve and TNFi-IR PsA patients with baseline plaque psoriasis (≥3% BSA) and nail involvement (mNAPSI > 0). Significant improvements versus placebo were observed at week 16 and sustained through week 52. The study included randomized, placebo-controlled phase 3 trials BE OPTIMAL and BE COMPLETE, followed by an open-label extension BE VITAL. Safety profiles showed no new signals over one year.

Key Findings

• Bimekizumab treatment led to clinically meaningful improvements across joint, skin, and nail domains at week 16 compared to placebo.
• These improvements were consistent and sustained through week 52 in both biologic-naïve and TNFi-IR patients.
• Bimekizumab was well tolerated with no new safety signals identified during the one-year treatment period.
• Nail clearance was achieved and maintained, addressing a key domain associated with severe disease and poor quality of life.
• The dosing regimen of 160 mg every 4 weeks aligns with global regulatory approvals for PsA treatment.

Clinical Implications

Bimekizumab offers a valuable treatment option for PsA patients with concomitant significant skin and nail involvement, addressing multiple disease domains simultaneously. Its sustained efficacy and favorable safety profile support its use in both biologic-naïve and TNFi-IR populations. Clinicians should consider bimekizumab when aiming for comprehensive disease control and improved quality of life in this challenging patient subgroup.

Conclusion

Bimekizumab provides sustained, clinically meaningful improvements across joint, skin, and nail manifestations in PsA patients with significant plaque psoriasis and nail involvement, with a favorable safety profile over one year. These findings support its role as an effective therapeutic option in this population.

References

1. BE OPTIMAL, BE COMPLETE, BE VITAL Phase 3 Studies -- Bimekizumab in Psoriatic Arthritis